Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Valent

Showing results (91-100 of 662) with videos related to

Pageof 67
Sort By:
Leukemia Research|April 18, 2008
Improvement of cardiac function, mitral regurgitation and pulmonary hypertension in a patient with chronic eosinophilic leukemia (CEL) after low dose imatinib therapyMaria-Theresa Krauth, Thomas Binder, Leopold Ohler, et al.
International Archives of Allergy and Immunology|March 29, 2002
Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic conceptsFrédéric Féger, Antoine Ribadeau Dumas, Laurence Leriche, et al.
Immunology and Allergy Clinics of North America|September 27, 2023
World Health Organization Classification and Diagnosis of Mastocytosis: Update 2023 and Future PerspectivesPeter Valent, Karl Sotlar, Hans-Peter Horny, et al.
Leukemia & Lymphoma|April 10, 2008
Diagnostic and prognostic value of new biochemical and immunohistochemical parameters in chronic myeloid leukemiaPeter Valent, Hermine Agis, Wolfgang Sperr, et al.
Oncotarget|September 2, 2016
Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myelomaKatharina Blatt, Harald Herrmann, Gabriele Stefanzl, et al.
The Journal of Allergy and Clinical Immunology|May 3, 2022
Massive release of T<sub>H</sub>2 cytokines induced a cytokine storm during a severe mast cell activation event in a patient with indolent systemic mastocytosisThomas Boehm, Robin Ristl, Jakob Mühlbacher, et al.
International Archives of Allergy and Immunology|October 31, 2002
Individual hymenoptera venom compounds induce upregulation of the basophil activation marker ectonucleotide pyrophosphatase/phosphodiesterase 3 (CD203c) in sensitized patientsMarc Binder, Gerhard Fierlbeck, Te iaoP King, et al.
Seminars in Hematology|March 28, 2012
Controversies and open questions in the definitions and classification of the hypereosinophilic syndromes and eosinophilic leukemiasPeter Valent, Hans-Peter Horny, Bruce S Bochner, et al.
The Journal of Allergy and Clinical Immunology. in Practice|November 24, 2025
Diagnosis and Management of Patients With Mast Cell Activation Syndromes: Status 2026Cem Akin, Theo Gülen, Mariana C Castells, et al.
Eclinicalmedicine|January 29, 2025
Characterization of patients with clonal mast cells in the bone marrow with clinical significance not otherwise specifiedThomas Ballul, Vito Sabato, Peter Valent, et al.
Pageof 67

Showing results (91-100 of 662) with videos related to

Sort By:
Pageof 67
Leukemia Research|April 18, 2008
Improvement of cardiac function, mitral regurgitation and pulmonary hypertension in a patient with chronic eosinophilic leukemia (CEL) after low dose imatinib therapyMaria-Theresa Krauth, Thomas Binder, Leopold Ohler, et al.
International Archives of Allergy and Immunology|March 29, 2002
Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic conceptsFrédéric Féger, Antoine Ribadeau Dumas, Laurence Leriche, et al.
Immunology and Allergy Clinics of North America|September 27, 2023
World Health Organization Classification and Diagnosis of Mastocytosis: Update 2023 and Future PerspectivesPeter Valent, Karl Sotlar, Hans-Peter Horny, et al.
Leukemia & Lymphoma|April 10, 2008
Diagnostic and prognostic value of new biochemical and immunohistochemical parameters in chronic myeloid leukemiaPeter Valent, Hermine Agis, Wolfgang Sperr, et al.
Oncotarget|September 2, 2016
Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myelomaKatharina Blatt, Harald Herrmann, Gabriele Stefanzl, et al.
The Journal of Allergy and Clinical Immunology|May 3, 2022
Massive release of T<sub>H</sub>2 cytokines induced a cytokine storm during a severe mast cell activation event in a patient with indolent systemic mastocytosisThomas Boehm, Robin Ristl, Jakob Mühlbacher, et al.
International Archives of Allergy and Immunology|October 31, 2002
Individual hymenoptera venom compounds induce upregulation of the basophil activation marker ectonucleotide pyrophosphatase/phosphodiesterase 3 (CD203c) in sensitized patientsMarc Binder, Gerhard Fierlbeck, Te iaoP King, et al.
Seminars in Hematology|March 28, 2012
Controversies and open questions in the definitions and classification of the hypereosinophilic syndromes and eosinophilic leukemiasPeter Valent, Hans-Peter Horny, Bruce S Bochner, et al.
The Journal of Allergy and Clinical Immunology. in Practice|November 24, 2025
Diagnosis and Management of Patients With Mast Cell Activation Syndromes: Status 2026Cem Akin, Theo Gülen, Mariana C Castells, et al.
Eclinicalmedicine|January 29, 2025
Characterization of patients with clonal mast cells in the bone marrow with clinical significance not otherwise specifiedThomas Ballul, Vito Sabato, Peter Valent, et al.
Pageof 67